Psoriasis Treatment Market Size, Share, Growth, and Industry Analysis, By Type (TNF Inhibitors, Phosphodiesterase Inhibitors, Interleukin Blockers, Others), By Application (Oral, Injectable), Regional Insights and Forecast to 2035

Psoriasis Treatment Market Overview

The global psoriasis treatment market is projected to grow from USD 32,918.64 million in 2026 to USD 59,466.41 million by 2035. The market is expected to expand at a steady compound annual growth rate (CAGR) of 6.79% during the forecast period from 2026 to 2035, driven by increasing prevalence of psoriasis, advancements in treatment options, and rising demand for effective therapeutic solutions.

The psoriasis treatment market is expanding due to increasing awareness about chronic skin disorders, advancements in biologic therapies, and rising demand for targeted treatment options. Psoriasis affects millions of people globally and requires long-term management through medications that reduce inflammation and improve skin health. In 2024, interleukin blockers represented the leading treatment category with 42% market share due to their high effectiveness and targeted immune response. The market includes biologics, oral therapies, injectable treatments, and emerging precision medicines designed to improve patient outcomes. Growing research activities and improved healthcare access continue to support innovation in psoriasis treatment solutions.

The USA psoriasis treatment market is driven by high adoption of advanced biologic therapies, strong healthcare infrastructure, and increasing diagnosis of chronic inflammatory skin conditions. The country has significant demand for injectable treatments due to their effectiveness in managing moderate to severe psoriasis cases. In 2024, North America accounted for 38% market share of the global psoriasis treatment market, supported by the USA healthcare system and widespread availability of advanced therapies. Pharmaceutical companies are focusing on innovative biologics, personalized treatment approaches, and improved patient support programs. Rising awareness among patients and healthcare professionals continues to influence treatment adoption across the USA.

Key Findings

• Market Size and Forecast: The psoriasis treatment market size was valued at USD 32,918.64 million in 2026 and is projected to reach USD 59,466.41 million by 2035with a CAGR of 6.79%.
• Type Leadership: Interleukin blockers dominated psoriasis treatment market with 42% share due to targeted therapies and improved patient response outcomes.
• Application Leadership: Injectable treatments led psoriasis therapy applications with 64% share driven by biologics adoption and moderate severity management.
• Key Company Landscape: AbbVie and Novartis lead psoriasis treatment through innovative biologics, research capabilities, and global healthcare market presence.
• Fastest Growing Region: North America held 38% market share supported by advanced healthcare systems, biologic adoption, and treatment accessibility.
• Key Trends: Personalized therapies, immune-targeted treatments, and biologic innovations are shaping psoriasis care with increasing focus on treatment precision.

Latest Trends

The psoriasis treatment market is witnessing significant transformation due to advancements in biologic drugs, immune pathway targeting, and personalized healthcare approaches. Pharmaceutical companies are focusing on therapies that selectively target inflammatory pathways associated with psoriasis progression. In 2024, interleukin blockers maintained a leading position with 42% market share because of their strong clinical effectiveness and adoption among patients requiring advanced treatment options. Injectable therapies are gaining importance as they provide sustained treatment benefits for moderate to severe psoriasis conditions. The development of oral therapies with improved safety profiles is also creating new opportunities for patients seeking convenient treatment options. Digital healthcare platforms and remote patient monitoring systems are supporting improved disease management and treatment adherence. Research activities are increasingly focused on combination therapies, novel immune modulators, and precision medicine approaches. Increasing awareness about early diagnosis and available treatment options is encouraging more patients to seek medical care. Companies are investing in clinical research to develop therapies with improved efficacy, reduced side effects, and better patient experiences across different psoriasis categories.

Market Dynamics

DRIVER

"Rising demand for advanced biologic therapies"

The growing demand for advanced biologic therapies is a major driver for the psoriasis treatment market. Biologic medicines provide targeted action against immune pathways responsible for psoriasis development, making them effective for patients with moderate to severe conditions. Increasing diagnosis rates and improved awareness about available treatment options are encouraging patients to adopt advanced therapies. Healthcare providers are increasingly recommending biologics due to their ability to provide long-term disease control and improved quality of life. In 2024, injectable treatments accounted for 64% market share due to widespread adoption of biologic therapies. Pharmaceutical companies are expanding research programs to develop innovative therapies targeting specific immune mechanisms. The increasing availability of specialized dermatology care and improved reimbursement systems in developed regions are also supporting market growth.

RESTRAINT

" High treatment costs and limited accessibility"

The psoriasis treatment market faces challenges due to high costs associated with advanced biologic medicines and limited accessibility in some regions. Many innovative therapies require significant investment in research, development, and manufacturing, which can influence treatment affordability. Patients in developing countries may experience difficulties accessing advanced psoriasis therapies due to limited healthcare infrastructure and reimbursement limitations. Long-term treatment requirements can also create financial challenges for patients managing chronic conditions. Healthcare providers must balance treatment effectiveness with affordability when selecting therapy options. Companies are working on developing alternative treatment solutions, biosimilars, and improved distribution strategies to increase accessibility. Addressing affordability concerns remains important for expanding access to advanced psoriasis treatments worldwide.

OPPORTUNITY

"Growth in personalized psoriasis treatment approaches"

The increasing focus on personalized medicine creates significant opportunities for the psoriasis treatment market. Advances in immunology and biotechnology are enabling the development of therapies designed for specific patient profiles and disease characteristics. Personalized treatment strategies can improve therapy selection, patient response, and long-term disease management. Pharmaceutical companies are investing in research to identify new biological targets and develop more precise treatment options. The growing adoption of diagnostic technologies and biomarker-based approaches is supporting customized psoriasis care. In 2024, interleukin blockers represented 42% market share, reflecting strong demand for targeted immune therapies. Emerging opportunities include combination treatments, next-generation biologics, and improved patient monitoring systems that support more effective psoriasis management.

CHALLENGE

"Managing treatment resistance and disease complexity"

The psoriasis treatment market faces challenges related to treatment resistance, disease variability, and long-term patient management. Psoriasis is a complex immune-mediated condition with different severity levels and responses to therapy. Some patients may experience reduced effectiveness over time, requiring adjustments in treatment strategies. Healthcare professionals must evaluate multiple factors, including disease progression, patient history, and therapy response. Developing treatments that provide consistent outcomes across diverse patient populations remains a major research challenge. Companies are investing in advanced clinical studies to understand disease mechanisms and improve therapeutic performance. The need for safer, more effective, and durable treatment solutions continues to influence innovation within the psoriasis treatment market.

Psoriasis Treatment Market Segmentation

The psoriasis treatment market segmentation is based on treatment type and application, reflecting different approaches used for managing mild, moderate, and severe psoriasis conditions. Treatment categories include TNF inhibitors, phosphodiesterase inhibitors, interleukin blockers, and other emerging therapies. Applications are divided into oral and injectable treatments based on administration methods and patient requirements. In 2024, interleukin blockers accounted for 42% market share due to targeted immune pathway action and strong clinical adoption. Injectable treatments represented 64% market share because of increasing use of biologic therapies. The segmentation highlights growing demand for effective, personalized, and advanced psoriasis treatment solutions worldwide.

By Type

Based on Type the global market can be categorized in to TNF Inhibitors, Phosphodiesterase Inhibitors, Interleukin Blockers, and Others.

• TNF Inhibitors: TNF inhibitors accounted for 28% market share in the psoriasis treatment market in 2024 and remain an important therapy category for managing inflammatory skin conditions. These therapies work by blocking tumor necrosis factor pathways involved in immune system activation and inflammation. TNF inhibitors are widely used for moderate to severe psoriasis cases and have established clinical acceptance among dermatologists. The segment continues to benefit from long-term physician experience, broad treatment availability, and effectiveness in controlling inflammatory symptoms. Pharmaceutical companies are focusing on improving treatment convenience and developing optimized formulations. The increasing adoption of biologic therapies supports continued demand for TNF inhibitors, especially among patients requiring systemic treatment options. The segment also benefits from expanding awareness about advanced psoriasis management approaches.

• Phosphodiesterase Inhibitors: Phosphodiesterase inhibitors represented 12% market share in 2024 and provide an oral treatment option for psoriasis patients seeking non-injectable therapies. These medicines regulate inflammatory responses by modifying intracellular signaling pathways associated with immune activity. The segment is gaining attention due to increasing patient preference for convenient oral administration methods. Phosphodiesterase inhibitors are used for managing symptoms and improving disease control in selected patient groups. Pharmaceutical companies are investing in research to improve efficacy profiles and expand therapeutic applications. The demand for alternative treatment options beyond injectable biologics is supporting segment development. Growing focus on patient-friendly treatment approaches and improved medication adherence is creating opportunities for phosphodiesterase inhibitor adoption in psoriasis care.

• Interleukin Blockers: Interleukin blockers dominated the psoriasis treatment market with 42% market share in 2024 due to their targeted mechanism and strong effectiveness in controlling immune-related inflammation. These therapies specifically target interleukin pathways associated with psoriasis development, including inflammatory signals responsible for skin lesion formation. Interleukin blockers are widely adopted for moderate to severe psoriasis because of improved treatment outcomes and longer disease management benefits. The segment is supported by continuous innovation in biologic therapies and increasing physician preference for targeted treatment approaches. Pharmaceutical companies are developing next-generation interleukin-based therapies with improved safety and performance characteristics. Growing acceptance of precision medicine approaches is further strengthening demand for interleukin blockers across major healthcare markets.

• Others: Other psoriasis treatment types accounted for 18% market share in 2024 and include emerging therapies, topical treatments, and alternative systemic medications. These treatment options support patients with different disease severity levels and individual healthcare requirements. The segment includes developing therapeutic approaches designed to improve treatment flexibility and patient outcomes. Increasing research activities are contributing to the introduction of innovative psoriasis management solutions. Healthcare providers often consider these therapies based on patient condition, treatment history, and response patterns. The segment benefits from continuous development of new mechanisms and combination treatment approaches. Growing demand for personalized psoriasis care is creating opportunities for additional therapy categories.

By Application

Based on Application the global market can be categorized in to Oral and Injectable.

• Oral: Oral psoriasis treatments accounted for 36% market share in 2024 and remain an important option for patients requiring convenient medication administration. Oral therapies are preferred by some patients due to ease of use and avoidance of injection procedures. This application segment includes phosphodiesterase inhibitors and other systemic medications used for managing psoriasis symptoms. Increasing demand for patient-friendly treatment approaches is supporting development of advanced oral therapies with improved effectiveness and safety characteristics. Pharmaceutical companies are focusing on creating oral medications that provide better disease control while maintaining patient convenience. The segment continues to benefit from rising awareness about available psoriasis treatment options and growing demand for alternatives to injectable therapies.

• Injectable: Injectable treatments led the psoriasis treatment market with 64% market share in 2024 due to strong adoption of biologic therapies among patients with moderate to severe psoriasis. Injectable therapies provide targeted treatment by directly influencing immune pathways involved in disease progression. The segment includes interleukin blockers and TNF inhibitors that are widely used in advanced psoriasis management. Healthcare professionals frequently recommend injectable treatments because of their clinical effectiveness and ability to provide sustained disease control. Increasing adoption of biologics, improved patient support programs, and advancements in delivery systems are supporting segment expansion. Pharmaceutical companies are developing innovative injectable formulations with improved convenience and treatment performance to enhance patient experience.

Psoriasis Treatment Market Regional Outlook

• North America

North America accounted for 38% market share in the psoriasis treatment market in 2024, representing the largest regional market. The region benefits from advanced healthcare infrastructure, high adoption of biologic therapies, and strong pharmaceutical research capabilities. The USA represents the major contributor due to widespread availability of injectable treatments and specialized dermatology services. In 2024, injectable applications accounted for 64% market share globally, with North America showing strong demand for biologic-based treatment options. Pharmaceutical companies in the region are investing in innovative therapies targeting immune pathways associated with psoriasis. Increased awareness among patients and healthcare professionals supports early diagnosis and treatment adoption. The region also benefits from advanced reimbursement systems and access to specialized medical care. Growing interest in personalized treatment approaches and next-generation biologics continues to influence market development across North America.

• Europe

Europe accounted for 29% market share in the psoriasis treatment market in 2024, supported by strong healthcare systems, increasing adoption of biologic therapies, and growing awareness of chronic skin disorders. The region has a well-established dermatology sector with increasing demand for advanced psoriasis management solutions. Countries across Europe are adopting targeted therapies, including interleukin blockers and TNF inhibitors, for patients requiring systemic treatment options. In 2024, interleukin blockers represented 42% market share globally due to their targeted immune response and clinical effectiveness. European healthcare providers are increasingly focusing on personalized treatment strategies to improve patient outcomes. The region benefits from pharmaceutical research activities and availability of innovative therapies. Rising investments in healthcare infrastructure and improved access to specialized dermatological care continue to support psoriasis treatment adoption. The demand for injectable biologics remains strong due to increasing preference for effective therapies among patients with moderate to severe psoriasis conditions.

• Asia-Pacific

Asia-Pacific accounted for 22% market share in the psoriasis treatment market in 2024, driven by increasing disease awareness, expanding healthcare access, and improving pharmaceutical capabilities. The region is witnessing growing demand for advanced psoriasis treatments as diagnosis rates improve and healthcare systems develop. Countries including China, Japan, India, and South Korea are contributing to market expansion through increased adoption of modern therapies. In 2024, injectable treatments maintained 64% market share globally, with Asia-Pacific showing rising acceptance of biologic treatment options. Pharmaceutical companies are increasing investments in regional research, manufacturing, and distribution networks to improve availability of psoriasis medicines. The growth of specialty healthcare centers and increasing awareness among patients are supporting treatment adoption. The region also presents opportunities for oral therapies due to demand for convenient medication options. Expanding healthcare infrastructure and rising focus on chronic disease management continue to influence psoriasis treatment market development across Asia-Pacific.

• Middle East & Africa

Middle East & Africa accounted for 6% market share in the psoriasis treatment market in 2024, supported by improving healthcare infrastructure and increasing awareness of dermatological conditions. The region is experiencing gradual adoption of advanced psoriasis therapies as healthcare providers improve access to specialized treatments. Injectable biologics are gaining attention among patients requiring effective management of moderate to severe psoriasis cases. In 2024, interleukin blockers accounted for 42% market share globally, reflecting increasing demand for targeted immune-based treatments. The Middle East is witnessing higher adoption due to investments in advanced medical facilities and specialty care centers. African markets are gradually developing through improved healthcare services and increasing availability of pharmaceutical products. Challenges related to treatment affordability and accessibility remain important considerations. Companies are focusing on expanding distribution networks and developing solutions suitable for regional healthcare requirements.

• Rest of the World

Rest of the World accounted for 5% market share in the psoriasis treatment market in 2024, including Latin America and other emerging healthcare markets. The region is experiencing gradual growth due to increasing diagnosis, healthcare modernization, and rising awareness about available psoriasis treatment options. Patients are gaining improved access to biologic therapies and systemic medications as healthcare systems continue to develop. In 2024, oral treatments represented 36% market share globally, supporting demand for convenient treatment approaches in emerging markets. Healthcare providers are increasingly adopting advanced therapies to improve disease management outcomes. Pharmaceutical companies are expanding product availability and strengthening regional partnerships to reach more patients. Growth opportunities are supported by increasing investment in healthcare facilities, improved medical education, and rising awareness of chronic inflammatory diseases.

Key Industry Players

The psoriasis treatment market includes leading pharmaceutical companies focusing on biologic therapies, immune-targeted treatments, and innovative drug development strategies. Major companies are strengthening their positions through research and development activities, clinical advancements, product launches, and global healthcare partnerships. Key players are investing in interleukin blockers, TNF inhibitors, oral therapies, and injectable treatment solutions to address different psoriasis patient needs. Competitive strategies include expanding treatment portfolios, improving patient access programs, and developing next-generation therapies with enhanced effectiveness. Companies are also focusing on personalized medicine approaches to improve treatment selection and patient outcomes. The market remains competitive as pharmaceutical organizations continue advancing psoriasis treatment technologies.

List of Top Psoriasis Treatment Companies

• Novartis International AG
• Johnson & Johnson
• Pfizer Inc.
• Merck and Co. Inc.
• AbbVie and Amgen
• Eli Lilly

List of Top 2 Companies Market Share

• AbbVie: AbbVie holds 14% market share through advanced biologics, psoriasis therapies, and strong global treatment presence.
• Novartis International AG: Novartis holds 11% market share through interleukin blockers, research innovation, and specialized psoriasis medicines.

Investment Analysis and Opportunities

The psoriasis treatment market provides investment opportunities through increasing demand for biologic therapies, personalized medicine, and advanced immune-targeted treatments. Pharmaceutical companies are investing in research programs focused on improving treatment effectiveness, reducing side effects, and expanding therapy options. In 2024, interleukin blockers accounted for 42% market share, highlighting strong demand for targeted psoriasis treatment solutions. Growing adoption of injectable therapies and increasing healthcare access are creating opportunities for manufacturers developing innovative medicines. Investments are focused on clinical research, biosimilar development, digital healthcare support, and patient management solutions. Expansion into emerging healthcare markets also provides opportunities for companies seeking broader treatment accessibility.

New Product Development

New product development in the psoriasis treatment market focuses on biologic innovations, oral therapy improvements, and targeted immune pathway solutions. Pharmaceutical companies are developing advanced treatments designed to improve patient outcomes and provide longer disease control. In 2024, injectable therapies maintained 64% market share due to strong adoption of biologic treatment approaches. Research activities are focused on interleukin-based therapies, combination treatments, and improved drug delivery technologies. Companies are also exploring personalized treatment methods based on patient characteristics and disease response. The development of safer and more convenient psoriasis therapies continues to influence market innovation. Advanced clinical research is supporting the introduction of next-generation treatments for different psoriasis conditions.

Recent Developments

• January 2024 - AbbVie Expanded Advanced Psoriasis Treatment Development Programs

AbbVie expanded psoriasis treatment development programs by advancing biologic research, strengthening immune-targeted therapies, and improving treatment capabilities for patients requiring effective disease management solutions.

• March 2024 - Novartis International AG Enhanced Interleukin Based Therapy Research Initiatives

Novartis International AG enhanced interleukin therapy research initiatives by developing targeted treatments, supporting clinical innovation, and improving advanced biologic solutions for psoriasis patients.

• May 2024 - Eli Lilly Introduced Innovative Psoriasis Treatment Research Programs

Eli Lilly introduced innovative psoriasis research programs by expanding immune therapy studies, improving treatment approaches, and developing advanced solutions using biological medicine capabilities.

• July 2024 - Johnson & Johnson Strengthened Dermatology Treatment Portfolio Expansion

Johnson & Johnson strengthened dermatology portfolio expansion by improving psoriasis therapies, supporting research activities, and advancing treatment solutions through pharmaceutical innovation capabilities.

• September 2024 - Pfizer Inc. Advanced Oral Psoriasis Therapy Development Activities

Pfizer Inc. advanced oral psoriasis therapy development activities by investing in innovative medicines, improving treatment convenience, and expanding pharmaceutical research capabilities.

Report Coverage

The psoriasis treatment market report provides detailed analysis of treatment types, applications, regional performance, competitive landscape, and industry developments. The study covers TNF inhibitors, phosphodiesterase inhibitors, interleukin blockers, and other emerging therapies used for psoriasis management. It evaluates oral and injectable treatment applications across global healthcare markets. The report analyzes regional market performance across North America, Europe, Asia-Pacific, Middle East & Africa, and Rest of the World. It includes insights into leading companies, market trends, growth drivers, restraints, opportunities, challenges, product innovations, and strategic developments. The coverage highlights factors influencing psoriasis treatment adoption and the evolution of advanced therapeutic solutions worldwide.